QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Status:
Withdrawn
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination
therapy in subjects with with CD20-positive NHL who have progressed on or after rituximab
therapy.